Cardlytics (NASDAQ:CDLX) Announces Quarterly Earnings Results

Cardlytics (NASDAQ:CDLX) released its quarterly earnings data on Wednesday. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.08), Zacks reports. Cardlytics had a negative return on equity of 235.70% and a negative net margin of 44.12%.The business had revenue of $56.10 million during the quarter, compared to analyst estimates of $54.46 million.

Here are the key takeaways from Cardlytics’ conference call:

• Cardlytics says its 2025 reset delivered discipline and tech modernization — reporting full-year Adjusted EBITDA of $10.1M, Q4 Adjusted EBITDA of $8.5M, faster feature delivery (+20%) and lower infrastructure costs (-40%).
• The company ended its Bank of America relationship and faces content restrictions from a large FI, which the firm says is the primary driver of weak Q1 2026 guidance (billings down ~41%–35% YoY) and an expected negative Adjusted EBITDA of -$7.5M to -$3.5M.
• Management highlights strong advertiser traction — particularly in grocery, convenience and fashion/luxury — with Q4 U.K. revenue up >35% YoY, a 60% QoQ increase in new business wins, and large spend increases from key advertisers.
• The planned sale of Bridg to PAR Technology is expected to close this month and, per management, will bolster liquidity (they intend to liquidate received PAR shares to pay down the credit facility) and eliminate non-core costs.

Cardlytics Stock Performance

Shares of NASDAQ CDLX traded down $0.09 during midday trading on Thursday, reaching $0.81. 593,625 shares of the company traded hands, compared to its average volume of 774,899. The company has a market cap of $43.93 million, a price-to-earnings ratio of -0.39, a PEG ratio of 0.13 and a beta of 1.03. The stock has a 50-day moving average price of $1.06 and a 200 day moving average price of $1.37. Cardlytics has a 52 week low of $0.75 and a 52 week high of $3.28. The company has a debt-to-equity ratio of 2.87, a current ratio of 1.14 and a quick ratio of 1.14.

Insider Buying and Selling

In other Cardlytics news, CEO Amit Gupta sold 45,159 shares of the company’s stock in a transaction that occurred on Wednesday, February 18th. The stock was sold at an average price of $0.93, for a total value of $41,997.87. Following the completion of the sale, the chief executive officer directly owned 659,644 shares in the company, valued at $613,468.92. This represents a 6.41% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders sold a total of 117,875 shares of company stock worth $113,022 over the last quarter. 4.40% of the stock is owned by insiders.

Hedge Funds Weigh In On Cardlytics

Several hedge funds have recently modified their holdings of CDLX. Bank of America Corp DE raised its holdings in shares of Cardlytics by 262.7% in the 3rd quarter. Bank of America Corp DE now owns 1,632,786 shares of the company’s stock worth $3,968,000 after purchasing an additional 1,182,593 shares in the last quarter. Geode Capital Management LLC grew its position in Cardlytics by 3.3% in the fourth quarter. Geode Capital Management LLC now owns 654,472 shares of the company’s stock worth $753,000 after buying an additional 20,908 shares during the last quarter. UBS Group AG grew its position in Cardlytics by 112.5% in the third quarter. UBS Group AG now owns 458,066 shares of the company’s stock worth $1,113,000 after buying an additional 242,536 shares during the last quarter. Invesco Ltd. increased its holdings in shares of Cardlytics by 38.1% in the fourth quarter. Invesco Ltd. now owns 170,122 shares of the company’s stock valued at $196,000 after buying an additional 46,973 shares in the last quarter. Finally, Jane Street Group LLC lifted its position in shares of Cardlytics by 263.0% during the 2nd quarter. Jane Street Group LLC now owns 162,427 shares of the company’s stock valued at $267,000 after acquiring an additional 117,687 shares during the last quarter. 68.10% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on CDLX shares. Wall Street Zen lowered Cardlytics from a “hold” rating to a “sell” rating in a research report on Saturday, November 8th. Weiss Ratings restated a “sell (d-)” rating on shares of Cardlytics in a report on Monday, December 29th. Finally, Bank of America reaffirmed an “underperform” rating on shares of Cardlytics in a research report on Thursday. Three research analysts have rated the stock with a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Reduce” and a consensus target price of $2.25.

About Cardlytics

Cardlytics, Inc operates a purchase intelligence and marketing platform that connects advertisers with consumers through bank and credit card transaction data. The company partners with financial institutions to analyze anonymized purchase information, enabling brands to deliver highly targeted offers and rewards directly to customers’ online and mobile banking channels. By leveraging real-time insights into consumer spending habits, Cardlytics helps marketers optimize campaign performance and measure return on ad spend more accurately than traditional digital advertising methods.

At the core of Cardlytics’ offering is its proprietary purchase intelligence engine, which aggregates and anonymizes transaction data from partner banks and credit unions.